Cleveland Medical Devices Reports Favorable PTAB Outcomes in Five of Six ResMed IPR Challenges

Cleveland Medical Devices reported favorable PTAB outcomes in 5 of 6 inter partes review petitions filed by ResMed over Ohio patents. The PTAB found ResMed did not establish unpatentability in 4 final written decisions and denied institution in a fifth, with one favorable final decision for ResMed, while district-court infringement/damages issues remain pending. The update supports the strength of Cleveland’s CPAP and home-sleep-testing IP portfolio, but does not resolve infringement or financial damages.

Analysis

This is leverage, not a cash-flow event, until a district court turns surviving patent claims into an injunction or royalty stream. For RMD, the real risk is not a one-off damage award; it is a longer-lived “tax” on margin and valuation from legal spend, reserve building, and settlement pressure that can cap the multiple even if unit sales stay intact. The PTAB outcome also increases the chance that other sleep-tech plaintiffs use the same playbook, which is a second-order overhang on the category.

The market is likely to overread the decision as pro-plaintiff or pro-defendant when the more relevant question is claim scope. If the asserted patents survive prior-art attacks but are later construed narrowly, the economic impact can go from meaningful to negligible; conversely, broad construction would force RMD to choose between redesign, royalty, or a delayed launch strategy. That means the next 1-3 month catalyst is procedural, not operational: claim construction, case management, or settlement language will matter far more than the PTAB headline.

Contrarian view: the consensus may be underestimating how useful these survivals are as bargaining chips even without infringement findings. The plaintiff now has enough leverage to prolong uncertainty, but not enough to justify a full punitive de-rating yet. Over 6-18 months, the key falsifier is any district-court narrowing or noninfringement ruling; absent that, litigation noise should remain a persistent valuation discount rather than a stock-breaker.

Key Decisions for Investors

• RMD: use any 1-2 day relief rally to add downside protection via 1-3 month put spreads; this is a slow-burn legal overhang, not a near-term earnings hit, and the thesis breaks if claim construction sharply narrows scope.
• RMD holders: consider covered calls into the next procedural update if implied volatility is bid; the expected move is more likely to be sideways-to-down on legal uncertainty than a clean rerate higher.
• Relative value: short RMD vs long XLV or a lower-litigation med-tech basket over a 1-3 month horizon to isolate idiosyncratic IP risk; cover if the court signals noninfringement, a royalty cap, or a plaintiff-friendly settlement at immaterial economics.
• Watch item, not a trade: if RMD reclaims pre-news valuation while district-court milestones are still ahead, that creates a better entry for bearish exposure because the market would be pricing away a risk that has not been litigated out.